In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China

Xiaoyan Liao,Qianwen Liang,Xinlu Dai,Shigang Wu,Chaohui Duan,Zhaofan Luo,Xiaoying Xie
DOI: https://doi.org/10.3389/fmicb.2024.1504013
IF: 5.2
2024-11-24
Frontiers in Microbiology
Abstract:Introduction: Eravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce. This study aims to evaluate the activity of eravacycline against the common Gram-positive and Gram-negative bacteria isolates in Guangdong, China. Methods: The clinical isolates were collected from four centers between 1 November 2023 and 31 January 2024, and the susceptibility of eravacycline (MIC 50 , MIC 90 , and MIC) was determined using broth microdilution as a reference method and E-TEST strips to evaluate their consistency. A total of 594 strains were collected from the four centers, including Staphylococcus aureus ( n = 126), Enterococcus faecalis ( n = 58), Enterococcus faecium ( n = 29), Klebsiella pneumoniae ( n = 136), Escherichia coli ( n = 187), and Acinetobacter baumannii ( n = 58). Results and discussion: The MIC 50 and MIC 90 (mg/L) of eravacycline were 0.12 and 1 for S. aureus, 0.06 and 0.12 for E. faecalis , 0.06 and 0.5 for E. faecium , 0.25 and 0.5 for E. coli , 0.5 and 2 for K. pneumoniae , and 0.25 and 2 for A. baumannii . Based on the FDA and EUCAST breakpoints, the susceptibility of eravacycline against S. aureus was 46.03% vs. 83.33%, 56.90% vs. 94.93% against E. faecalis , and 62.07% vs. 79.31% in E. faecium . The susceptibility rates of E. coli and K. pneumoniae were 90.37% and 58.09, respectively. To evaluate the performance between the broth microdilution test (BMD) and ETEST methods, we compared essential agreement (EA), categorical agreement (CA), very major error (VME), and major error (ME). The results demonstrated that compared with BMD, eravacycline measured by ETEST had higher VME and ME referring to FDA breakpoints than EUCAST breakpoints in the Gram-positive isolates. Since there were no intermediate breakpoints for the eravacycline, the MIC values measured by the ETEST method might result in lower CA and higher VME and ME. This study provides MIC values of eravacycline against Gram-positive and Gram-negative pathogens in four hospitals in Guangdong Province, and eravacycline is an effective therapeutic candidate for common bacteria.
microbiology
What problem does this paper attempt to address?